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A meta-analysis of six randomised trials demonstrated that intensive followup in colorectal cancer was associated with an absolute
reduction in all-cause 5-year mortality of 10% (95% confidence interval (CI): 4–16) – however, only two percent (95% CI: 0–5) was
attributable to cure from salvage re-operations. We postulate that other factors, such as increased psychological well-being and/or
altered lifestyle, and/or improved treatment of coincidental disease may contribute to the remaining lives saved, and form important
future research questions.
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Approximately two-thirds of patients presenting with colorectal
cancer undergo resection with curative intent, and most subse-
quently enter protocols for long-term followup (Kievit, 2002). The
rationale for surveillance is three-fold: psychological support,
facilitation of audit, and an opportunity for the early detection and
treatment of recurrent disease, with potential improvement in
survival. Recently, the authors (Renehan et al, 2002b) reported a
meta-analysis of five randomised trials and demonstrated a
significant improvement in all-cause 5-year mortality in patients
followed intensively. A Cochrane review (Jeffery et al, 2002)
independently found similar results, and, subsequently, a sixth
randomised trial reported additional results supporting these
conclusions (Secco et al, 2002). These data offer the first direct
evidence that intensive followup improves survival, but fall short
of evaluating the mechanisms underlying the observed survival
benefit. This study updates and extends our previous meta-
analysis to explore the survival mechanisms associated with
intensive followup.
MATERIALS AND METHODS
The search strategy, inclusion and exclusion criteria, data
extraction, and study quality assessment have been published
elsewhere (Renehan et al, 2002b, 2004), with further details
at www.christie.man.ac.uk/profinfo/departments/surgery/default.
htm. The key features were:
  Updated search strategy (to December 2003) using Cochrane
methodology.
  Inclusion criteria were: randomised controlled trial; patients
with colorectal cancer treated surgically with curative intent;
randomisation at or shortly after surgery, and availability of
5-year survival data.
  Data were extracted independently by two investigators (AGR,
MPS).
  Important components of methodological quality, namely
adequacy of concealment of patients’ allocation to treatment
groups, double-blinding, and withdrawals, were assessed.
Statistical analysis
Meta-analyses were performed at two levels. First, comparisons of
events (e.g. all-cause deaths) for intensive vs conventional followup
were performed and pooled estimates expressed as risk ratios (RR)
and 95% confidence intervals (95% CIs). Second, estimates of the
proportion of overall lives gained, and lives gained through to
salvage re-operation, were calculated using absolute risk differ-
ences (and 95% CIs) (Deeks and Altman, 2001). The difference
between these estimates was taken as an estimate of the gain in
lives attributable to nonsalvage-related factors. Tests for hetero-
geneity were performed, and, if significant, sources of hetero-
geneity were explored. Random-effect methods were used
throughout and all tests were performed using STATAt version
7.0 (Stata corporation, College Station, TX, USA).
RESULTS
Baseline characteristics
There were six randomised controlled trials (Makela et al, 1995;
Ohlsson et al, 1995; Kjeldsen et al, 1997; Pietra et al, 1998;
Schoemaker et al, 1998; Secco et al, 2002) comprising 1679
participants, 858 assigned to intensive and 821 assigned
to conventional followup (webappendix1). The surveillance
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stests, and the frequency of their use, varied considerably
(webappendix2).
In general, trial methodology was moderate. Two trials (Pietra
et al, 1998; Schoemaker et al, 1998) reported allocation by open
cards or random number tables. Randomisation was stratified by
site and Dukes’ stage in two trials (Kjeldsen et al, 1997; Schoemaker
et al, 1998). Specifically, with relation to this analysis, blinding
of clinicians and/or assessors about interpretation of recurrence
detection and/or decisions about subsequent treatments were not
mentioned, except for one trial (Schoemaker et al, 1998). However,
followup rates among survivors were generally good.
Outcomes
There were 268 (31%) deaths in patients followed intensively
compared with 328 (40%) for those followed by conventional
regimens, giving a pooled RR estimate of 0.76 (95% CI: 0.67–0.86)
(Table 1). The recurrence rates for all sites were similar in both
arms (36 vs 37%), but re-operation rates favoured those intensively
followed (9 vs 6%: RR¼2.12, 95% CI: 1.43–3.15). For both
arms, the proportions successfully salvaged were low – 4 and 2%,
respectively.
The estimate of absolute risk difference for overall lives gained
from intensive followup was 10% (95% CI: 4–16), but only 2%
(95% CI: 0–5) was attributable to cure from salvage re-operation
(Figure 1). The difference (4–11%) suggests that factors other than
salvage may contribute to survival from intensive followup. There
was significant statistical heterogeneity (P¼0.009), which, after
exploration, was mainly due to the Pietra et al (1998) trial, a study
which had high re-operation rates among patients intensively
followed (20 vs 6%). After excluding this study, the absolute risk
difference for all lives gained was 9% (95% CI: 2–16; w4
2¼6.70,
P¼0.15); that for lives gained through salvage was 1% (95% CI:
0–3; w4
2¼6.38, P¼0.17).
DISCUSSION
The findings of this study add to earlier meta-analyses (Jeffery et al,
2002; Renehan et al, 2002b; Figueredo et al, 2003), indicating
improved survival with intensive followup after curative resection
for colorectal cancer. In exploring the mechanisms of this benefit,
the present study shows that salvage surgery offers a ‘second chance’
of cure in a small number of cases (up to 5%), but that an additional
4–11% gain in survival may be attributable to other factors.
There are a number of potential limitations to this interpreta-
tion. Blinding of outcome assessment was generally poorly
reported, such that factors determining the decision to re-operate
may be biased. On the other hand, in one trial (Secco et al, 2002), a
substantial proportion of control patients had ‘asymptomatic’
recurrences, suggesting that the intervention (i.e. intensive
followup) may have contaminated the control arm. Other
limitations included the clinical heterogeneity of followup regi-
mens among the trials considered, the lack of quality of life data,
and that most of the included trials were carried out over a decade
age and thus may not represent contemporary oncological
practice. Additionally, even within a meta-analysis of six trials,
the number of recurrences treated and cured (disease-free) at the
end of the study period was small, and, consequently, estimates of
risk differences for disease-free status post-salvage surgery were
associated with wide CIs.
An advantage of the present analysis is that it brings together a
number of randomised studies, which individually were too small
to address followup mechanisms. Only studies where randomisa-
tion occurred at the time of initial surgery were included, and
survival was calculated at 5 years after initial treatment, hence
circumventing potential lead and lag biases. The reported absolute
overall survival benefit of 10% is similar to that estimated
independently by others (Ohisson and Paisson, 2003), while
the figure of 2% of lives saved through salvage alone is close to
the 2.4% estimated using a recurrence–salvage–outcome model
(Kievit, 2002). This apparent discrepancy emphasises the impor-
tance of determining the effectiveness of colorectal cancer followup
based on all-cause mortality, as judging effectiveness simply based
on the number of asymptomatic recurrences detected and salvaged
underestimates the true potential impact of intensive followup.
From the observations in this study, we hypothesise that
factors other than salvage treatment may contribute to improved
survival in colorectal cancer followup. The following may be
relevant: (i) increased psychosocial support and well-being; (ii)
altered dietary and lifestyle factors and (iii) improved treatment of
coincidental disease. For the first postulate, there is evidence that
psychological therapies improve outcome in some cancer types
(Newell et al, 2002), and at least one randomised trial (Kuchler
et al, 1999) has shown improved survival using psychological
support techniques among patients with gastrointestinal malig-
nancies, of which one-third were colorectal cancers. Health-related
quality of life was determined in one trial included in the meta-
analysis (Kjeldsen et al, 1999), which showed a small benefit
associated with intensive followup. Moreover, based on observa-
tions in breast cancer patients, there is a perception that intensive
followup is associated with increased anxiety, but this has not
been demonstrated in studies of followup in patients with
colorectal cancer (Stiggelbout et al, 1997; Kjeldsen et al, 1999).
Indeed, in the Danish randomised trial (Kjeldsen et al, 1999), the
proportions of patients who were ‘never nervous’ favoured the
intensively followed group when evaluated both before and after
their planned clinical visit. In support of the second postulate,
persistence of adverse lifestyle factors, such as obesity (Calle et al,
2003) and continued smoking (Goodman et al, 1990) after
treatment of a primary malignancy, are associated with decreased
survival for certain cancer types. Furthermore, cancer survivors
tend to make substantial changes to their diet and lifestyle
(Patterson et al, 2003), though it is unclear whether these
adjustments are selfmotivated or a direct consequence of
health-care interventions. Changes in patient behaviour due to
feeling ‘observed’ are recognised – known as Hawthorne effects
(Braunholtz et al, 2001), but whether or not frequent clinical
assessments during colorectal cancer followup is relevant in this
regard merits further study. The third postulate is an example of
a ‘care effect’ within a trial (Braunholtz et al, 2001), and it is
conceivable that followup per se may be a sophisticated mechanism
of ensuring regular medical contact and may benefit patients
irrespective of their cancer.
Table 1 Summary estimates: random-effects methods
Intensive FU Control FU Risk ratio (95% CIs) Test for heterogeneity
All-cause deaths 268/858 (31) 328/821 (40) 0.76 (0.67, 0.86) w5
2¼5.51; P¼0.36
All site recurrences 313/858 (36) 307/821 (37) 0.94 (0.83, 1.06) w5
2¼1.55; P¼0.91
Re-operation rates 79/858 (9) 33/821 (4) 2.12 (1.43, 3.15) w5
2¼4.33; P¼0.50
Salvage cure rates 34/858 (4) 33/821 (2) 2.18 (0.86, 5.49) w5
2¼7.76; P¼0.17
Unless otherwise stated, values in parentheses are percentages. CI: confidence interval. FU: followup.
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implications for future health resources and research are
considerable. For decades, the majority of colorectal cancer
followup was performed by clinicians within surgical and/or
oncology clinics. Alternatives to this are emerging, and include
colorectal nurse specialists working in parallel with colorectal
cancer specialists using protocol-driven protocols (Renehan
et al, 2002a). In this setting, there may be a role for addi-
tional allied disciplines such as cancer nutritionists and psycho-
logists. These possibilities now form important future research
questions.
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